<code id='344B4E65D4'></code><style id='344B4E65D4'></style>
      • <acronym id='344B4E65D4'></acronym>
      <center id='344B4E65D4'><center id='344B4E65D4'><tfoot id='344B4E65D4'></tfoot></center><abbr id='344B4E65D4'><dir id='344B4E65D4'><tfoot id='344B4E65D4'></tfoot><noframes id='344B4E65D4'>
      • <optgroup id='344B4E65D4'><strike id='344B4E65D4'><sup id='344B4E65D4'></sup></strike><code id='344B4E65D4'></code></optgroup>
        5. <b id='344B4E65D4'><label id='344B4E65D4'><select id='344B4E65D4'><dt id='344B4E65D4'><span id='344B4E65D4'></span></dt></select></label></b><u id='344B4E65D4'></u>
          <i id='344B4E65D4'><strike id='344B4E65D4'><tt id='344B4E65D4'><pre id='344B4E65D4'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-28 00:03:26 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：218
                                  
                                    
          
                                   
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand.																									Adobe 
          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
          advertisement
          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          With psoriasis trial ahead, Alumis raises $259 million
                                
                            
          Next article：  
                                      
                                          How to save PrEP access — and even expand it
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles